EHMT2 and myelodysplastic syndrome: Currently, the group of epigenetic drugs includes256,257 DNMTis (such as decitabine used in the treatment of AML and high-risk myelodysplastic syndromes,258 and 5-azacitidine used in high-risk myelodysplastic syndromes259), HDAC inhibitors (like TSA mentioned earlier, activating autophagy in osteosarcoma235), HAT inhibitors (curcumin can reduce IL-6 secretion in RA248), histone methyltransferase inhibitors (BIX01294 inhibits G9a in multiple myeloma260), and various miRNA-based molecular targeted therapy drugs.